Strategic transactions and agreements - Ayala Pharmaceuticals - Fair value of assets acquired and liabilities (Details) - USD ($) $ in Thousands	Mar. 25, 2024	Dec. 31, 2024	Dec. 31, 2023
Assets acquired:
Other long-term assets		$ 4,411	$ 100
Total assets		240,241	148,540
Liabilities assumed:
Total liabilities		$ 59,076	$ 28,658
Ayala Asset Purchase Agreement
Asset acquisitions
Common stock issued	$ 50,645
Upfront consideration paid to Ayala	20,039
Transaction costs	657
Consideration paid	71,341
Assets acquired:
In-process research and development	73,382
Other long-term assets	2,480
Total assets	75,862
Liabilities assumed:
Accrued expenses	4,521
Total liabilities	4,521
Net assets acquired	$ 71,341